Last reviewed · How we verify

5-Fluorouracil plain powder

Al-Azhar University · FDA-approved active Small molecule Quality 0/100

5-Fluorouracil plain powder is a Small molecule drug developed by Al-Azhar University. It is currently FDA-approved.

5-Fluorouracil plain powder, marketed by Al-Azhar University, is an established chemotherapy agent with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and long-standing use in treating various cancers, providing a strong foundation in the market. The primary risk is the potential increase in competition following the patent expiry in 2028, which could impact revenue and market share.

At a glance

Generic name5-Fluorouracil plain powder
SponsorAl-Azhar University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about 5-Fluorouracil plain powder

What is 5-Fluorouracil plain powder?

5-Fluorouracil plain powder is a Small molecule drug developed by Al-Azhar University.

Who makes 5-Fluorouracil plain powder?

5-Fluorouracil plain powder is developed and marketed by Al-Azhar University (see full Al-Azhar University pipeline at /company/al-azhar-university).

What development phase is 5-Fluorouracil plain powder in?

5-Fluorouracil plain powder is FDA-approved (marketed).

Related